More on BBOT
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $9.89 |
|
|||
| Open | $10.45 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $11.02 | ||||
| Day Low | $9.96 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 370,335 | ||||
- BBOT publishes preclinical data on panKRAS inhibitor BBO-11818
- BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
- BridgeBio Oncology Therapeutics (BBOT) Reiterated at Buy by Stifel After Q4 Results
- BridgeBio Oncology Therapeutics, In (BBOT) PT Raised to $29 at H.C. Wainwright
- BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
- BBOT to Participate in Upcoming Investor Healthcare Conferences
- BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Stifel Starts BridgeBio Oncology Therapeutics, In (BBOT) at Buy
- Form 8-K Helix Acquisition Corp. For: Jan 22
- Form 4 Helix Acquisition Corp. For: Jan 26 Filed by: Chen Bihua
Entities mentioned with BBOT
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- SPAC | View Related Stories »
- Morgan Stanley | View Related Stories »
- Stifel | View Related Stories »
- S1 | View Related Stories »
- Show More...
